VistaGen Therapeutics (VTGN) Reports FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder
Tweet Send to a Friend
VistaGen Therapeutics Inc. (NASDAQ: VTGN) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


